Clinical and electrophysiological characteristics of patients having atrial flutter with 1:1 atrioventricular conduction
|
|
- Emma Whitehead
- 5 years ago
- Views:
Transcription
1 Europace (2008) 10, doi: /europace/eun012 of patients having atrial flutter with 1:1 atrioventricular conduction Mihoko Kawabata*, Kenzo Hirao, Kouji Higuchi, Takeshi Sasaki, Toshiyuki Furukawa, Hiroyuki Okada, Hitoshi Hachiya, and Mitsuaki Isobe Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Yushima, Bunkyo-ku, Tokyo , Japan Received 15 October 2007; accepted after revision 7 January 2008; online publish-ahead-of-print 7 February 2008 KEYWORDS Atrial flutter; 1:1 AV conduction; Syncope; Exercise; Sympathetic tone Introduction Atrial flutter (AFL) with 1:1 atrioventricular (AV) conduction (1:1 AFL) can be associated with haemodynamic compromise and require emergency treatment. Treatment with antiarrhythmic agents (AAs) can provoke this disorder by decreasing the atrial rate. Therefore, use of an AA in combination with a drug that slows conduction through the AV node is recommended. Beta-blockers have been proposed as candidate drugs. 1,2 However, negative dromotropic medication is not always effective. 3 7 The purposes of this retrospective study were to identify clinical and electrophysiological characteristics of patients who had suffered 1:1 AFL and to identify risk factors for this hazardous arrhythmia. * Corresponding author. Tel: þ ; fax: þ address: mihoko_kawabata.cvm@tmd.ac.jp Aims The purpose of this retrospective study was to assess characteristics of patients who had suffered atrial flutter (AFL) with 1:1 atrioventricular (AV) conduction (1:1 AFL). Methods and results Subjects were 8 patients ( years) with documented 1:1 AFL, and 101 AFL patients without a history of 1:1 AFL (control patients). 1:1 AFL occurred during physical activity with a ventricular rate of bpm. Antiarrhythmic agents were administered to all eight 1:1 AFL patients, whereas AV nodal conduction-suppressing agents were administered to four. The maximum ventricular rate at which 1:1 AV conduction occurred was significantly lower than when spontaneous 1:1 AFL occurred (164 vs. 218 bpm, P, 0.05). The 1:1 AFL patients had a significantly longer AFL cycle length (CL) (292 vs. 258 ms, P, 0.05) and more rapid AV nodal conduction time (maximum 1:1 AV conduction: 375 vs. 464 ms, P, 0.05) than did control. Arrhythmia had occurred in patients with an AFL CL 250 ms and a CL of maximum 1:1 AV conduction 400 ms. Conclusion Clinicians should be aware of the potential for 1:1 AV conduction in AFL patients, especially in those with remarkable prolongation of the CL in addition to enhanced AV conduction. Methods Study population Eight patients with clinically documented 1:1 AFL were included in the study: seven men (87%) and one woman, with a mean age of years (range years). The mean duration of AFL was 44 months (range months). Two patients had underlying cardiovascular disease, old myocardial infarction in one, and tachycardia-induced cardiomyopathy in the other. Characteristics of these patients were compared with those of 101 consecutive patients (control group) who were referred to our institution for RF ablation of AFL between March 1997 and October 2006 but who had no history of 1:1 AV conduction during AFL [89 men (88%) and 12 women; mean age years, range years). Fifty-four of these patients had cardiovascular disease: ischaemic heart disease (n ¼ 14), hypertrophic cardiomyopathy (n ¼ 6), postcardiac surgery state (n ¼ 8), dilated cardiomyopathy (n ¼ 2), pericarditis (n ¼ 2), tachycardia-induced cardiomyopathy (n ¼ 2), and cor pulmonae (n ¼ 1). Ten patients had sick sinus syndrome (three with a pacemaker). Primary hypertension was diagnosed in Published on behalf of the European Society of Cardiology. All rights reserved. & The Author For permissions please journals.permissions@oxfordjournals.org.
2 Life-threatening pro-arrhythmia, 1:1 AFL patients. The mean duration of AFL in the control group was 37 months (range 3 days 420 months). Patient evaluations Demographic data, pertinent prior medical history, symptoms, treatment history, and physical findings were obtained from the clinical records of each patient. A 12-lead electrocardiogram (ECG) was recorded, and duration of the PR interval during sinus rhythm and cycle length (CL) during AFL were automatically measured. Two-dimensional echocardiographic parameters [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter, and left atrial diameter (LAD)] were obtained for each patient. Electrophysiological study Written informed consent was obtained from all patients for electrophysiological study (EPS). Electrophysiological study was performed without interruption of AA and AV nodal-blocking drugs to assess AV nodal conduction, including atrial pacing at incremental rates to determine the maximal rate of consistent 1:1 AV conduction and programmed atrial stimulation with one extrastimulus. Measurement of the CL and AH and HL intervals was also performed during sinus rhythm. Statistical analysis All data are reported as mean + SD. Differences in continuous variables were analysed with unpaired Student s t-test, and the x 2 test was used to assess homogeneity in contingency tables. P, 0.05 was considered statistically significant. SPSS version was used for all statistical analyses. Results Atrial flutter with 1:1 atrioventricular conduction In all eight 1:1 AFL patients, arrhythmia had occurred during physical activity. The ventricular rate of arrhythmia was bpm (range bpm). Syncope accompanied arrhythmia in five patients, near syncope in two, and a shock state in one. Both patients with underlying heart disease suffered syncope during 1:1 AFL. of the patients with 1:1 atrial flutter The average LVEF was % (range 28 79%), and LAD was mm (range mm) (Table 1). All eight patients had been treated with an AA. This was to prevent paroxysmal AFL in five patients and paroxysmal atrial fibrillation (AF) in three. A class Ia drug (cibenzoline) was administered to two patients, class Ic drugs were administered to five patients (flecainide to two, pilsicainide to three), and a class III drug (amiodarone) was administered to one patient. Meanwhile, an AV nodal conductionsuppressing agent was given to four of these patients [atenolol (25 mg) to one, verapamil (120 or 320 mg) to two, and digoxin (0.125 mg) to one]. The PR interval of the surface ECG was not short in any of the eight patients (range ms, mean ms). The AFL CL was ms ( ms). During EPS, the AH interval varied from 65 to 100 ms (mean ms). There was no AV nodal duality property with a single premature atrial extrastimulus. The maximum pacing rate at Table 1 of patients with and without 1:1 atrial flutter Patients with 1:1 AFL (n ¼ 8) Patients without 1:1 AFL (n ¼ 101) P-value Age (years) NS Male/female 7/1 89/12 NS Underlying cardiac NS disease (%) LA diameter (mm) NS EF (%) NS LVDd (mm) NS Duration of AFL NS (months) Antiarrhythmic NS drugs (%) AV node-blocking NS agents (%) Beta-blocking NS agents (%) Heart rate in SR NS (bpm) PR interval (ms) NS CL of AFL (ms) ,0.05 CL of SR (ms) NS AH interval (ms) ,0.1 HV interval (ms) NS Maximum 1:1 AV ,0.05 conduction (ms) AV node duality (%) 0 29 NS % refers to the percentage of patients per group. EF, ejection fraction; LA, left atrium; LVDd, left ventricular end-diastolic diameter; NS, not significant; SR, sinus rhythm. which 1:1 AV conduction was maintained was ms (range ms). In all eight patients, second-degree AV block developed during atrial pacing at rates lower than those during which 1:1 AV conduction was sustained during spontaneous AFL (164 bpm during atrial pacing vs. 218 bpm during spontaneous 1:1 AFL; P, 0.05, Figure 1). The ECG of a 44-year-old man without any underlying heart disease but who suffered 1:1 AFL during exercise under administration of 100 mg/day cibenzoline and 25 mg/day atenolol is shown in Figure 2. This patient s blood pressure was 60 mmhg during 1:1 AFL. After intravenous injection of 2.5 mg verapamil, the AV conduction was suppressed to 4:1. of the control group At least 1 AA had been administered to 77 of the control patients (76%) (Table1). This was to prevent paroxysmal AFL in 21, paroxysmal AF in 54, ventricular tachycardia in 1, and atrial tachycardia in 1. Class Ia drugs were administered to 22 of these patients (cibenzoline to 17, disopyramide to 4, procainamide to 1). A class Ib drug (aprindine) was administered to five patients; class Ic drugs were administered to 36 patients (flecainide to 11, pilsicainide to 23, propafenone to 2); class III drugs were administered to seven patients (amiodarone to four, sotalol to two,
3 286 M. Kawabata et al. with 1:1 AFL had a significantly longer AFL CL (292 vs. 258 ms, P, 0.05) and more rapid AV nodal conduction time (maximum 1:1 AV conduction: 375 vs. 464 ms, P, 0.05) than did the control patients. All 1:1 AFL patients except one had a longer AFL CL than the average CL of the control patients. 1:1 AFL had occurred in patients with a CL during AFL 250 ms and a CL of maximum 1:1 AV conduction 400 ms (Figure 3). Figure 1 The rate of maximum 1:1 atrioventricular conduction during spontaneous 1:1 atrial flutter and during atrial pacing in patients with clinically documented 1:1 atrial flutter. The rate of maximum 1:1 atrioventricular conduction during atrial pacing was less than that during clinical 1:1 atrial flutter in all patients ( bpm during atrial pacing vs bpm during spontaneous 1:1 atrial flutter; P, 0.05). Figure 2 Electrocardiograms of a 44-year-old man. Left: atrial flutter (cycle length, 255 ms) with 1:1 atrioventricular conduction exhibiting right bundle branch block during exercise under administration of 100 mg/day cibenzoline and 25 mg/day atenolol. Blood pressure was 60 mmhg. Right: after intravenous injection of 2.5 mg verapamil, atrioventricular conduction was suppressed to 4:1. sematilide to one); and a class IV drug (bepridil) was administered to one patient. The remaining six patients were given two different AAs in combination (bepridil þ flecainide to three patients, cibenzoline þ pilsicainide to one, disopyramide þ cibenzoline to one, pilsicainide þ bepridil to one). To depress AV nodal conduction, beta-blockers were given to 28 patients, verapamil to 31, diltiazem to 3, and digoxin to 12. The PR interval of the surface ECG was ms, and the CL during AFL was ms. During EPS, the AH interval was ms, the rate of maximum 1:1 AV conduction was ms. Comparison of 1:1 atrial flutter patients and control patients There were no significant differences in clinical characteristics between the two study groups (Table1). The patients Discussion Major findings The present study revealed that in all eight 1:1 AFL patients, arrhythmia had occurred during physical activity and caused a potentially life-threatening haemodynamic state. Five patients suffered syncope, two suffered near syncope, and one suffered a shock state. Two patients had underlying heart disease. In all eight patients, the maximum rate at which 1:1 AV conduction occurred was significantly lower during atrial pacing than when the 1:1 AFL was spontaneous. These patients had a significantly prolonged AFL CL and a significantly shorter CL of maximum 1:1 AV conduction than did the control patients despite the fact that AA administration did not differ between them. Atrial flutter with 1:1 AV conduction occurred in patients with a CL during AFL 250 ms and a CL of maximum 1:1 AV conduction 400 ms. Pro-arrhythmic effects of antiarrhythmic agents: prolongation of the atrial cycle length during atrial flutter AFL with 1:1 AV conduction is recognized as a pro-arrhythmic complication of antiarrhythmic therapy. 1,2 The mechanism of the 1:1 ventricular response in AFL during administration Figure 3 Scatter plot of the cycle length during atrial flutter and cycle length of maximum 1:1 atrioventricular conduction. Atrial flutter with 1:1 atrioventricular conduction was observed in patients with a cycle length during atrial flutter 250 ms and a cycle length of maximum 1:1 atrioventricular conduction 400 ms.
4 Life-threatening pro-arrhythmia, 1:1 AFL 287 of AA is two-fold: (i) a prolongation in the AFL CL occurs due to drug-induced depression of atrial conduction velocity; (ii) if the atrial rate is slowed sufficiently, the AV node may permit 1:1 AV conduction under weak action of the AA on the AV node. All eight patients with 1:1 AFL had been treated with an AA. The AA attributed to the significant slowing of the atrial rate enough to allow acceleration of the ventricular response during AFL; however, there was no significant difference in the percentage of patients given an AA between the 1:1 AFL group and the control group (100 vs. 76%). Structural heart disease is known to increase the risk of ventricular pro-arrhythmia However, it was not a risk factor for pro-arrhythmias in the AFL patients. Enhanced atrioventricular conduction with increasing sympathetic tone The ventricular response during AFL is determined by the refractory period of the AV node, the degree of concealed conduction within the node, and the level of autonomic tone. Pre-existing rapid AV nodal conduction can also be a predisposing factor for the occurrence of 1:1 AFL. Although 1:1 AV conduction during AFL is thought to be unusual in the absence of AA therapy, there have been a few reports of this phenomenon None of the reported patients had electrocardiographic evidence of preexcitation, such as an abnormally short PR interval or delta waves during sinus rhythm. However, EPS suggested that some patients may have had either partial AV nodal bypass tracts with a shorter refractory period than the AV node or an AV node with unusual capacity for rapid conduction. 14,15 In our patients, the normal PR and AH intervals excluded total AV nodal bypass. Although EPS showed AV conduction to be within normal range, all the eight of our patients had 1:1 AFL during physical activity, which might have heightened sympathetic tone. The association of 1:1 AFL with high catecholamine states, such as exercise, is well documented. 3 Like other reported patients, 13,14,16 our patients showed that the maximum rate at which 1:1 AV conduction occurred was significantly lower during atrial pacing than when spontaneous 1:1 AFL was present. Sympathetic tone might play an important role in the occurrence of 1:1 AFL, making it more difficult to detect patients at risk of 1:1 AFL and to forecast sufficient amounts of negative dromotropic agents needed for prevention on the basis of basal characteristics. Previous reports Brembilla-Perrot et al. 17 reported that rapid AV nodal conduction indicated by a short PR interval on the surface EGG and continuity between the P wave and QRS complex on the signal-averaged ECG is a predisposing factor for the development of 1:1 AFL under administration of class I AAs. Like us, they showed that age and the presence of underlying heart disease do not predict the occurrence of 1:1 AFL. Although they did not mention the AFL CL, our results revealed the importance of two factors underlying 1:1 AFL: CL during AFL and a property of enhanced AV nodal conduction particularly under heightened sympathetic tone. Limitations Our study was limited by the fact that a stress test was not performed. Isoproterenol (ISP) was injected during evaluation of the AV conduction property in only one patient. Maximum 1:1 AV conduction improved in this patient from 340 to 270 ms with infusion of ISP. In contrast, the atrial CL during spontaneous 1:1 AFL was 316 ms. Because it is more likely that enhanced AV conduction occurred secondarily to heightened adrenergic tone and circulating catecholamines during 1:1 AFL under physical activity, the existence of an AV node with an unusual capacity for rapid AV conduction in an increasing sympathetic state could not be completely ruled out without the infusion of ISP. The study was also limited by its retrospective design and the small size of the 1:1 AFL group. Clinical implications We consider it mandatory to use drugs capable of slowing AV nodal conduction in addition to AA treatment to prevent 1:1 AFL. Although beta-blockers have been proposed as the best candidate drugs, use of these drugs does not guarantee protection against arrhythmia. The dosage must be adequate to surely suppress the AV conduction. To the best of our knowledge, this is the first reported study to assess the risk factors for 1:1 AFL on the basis of multiple clinical data, such as patient characteristics, ECG and EPS findings, and medical treatment including AA and AV node blockers. Results of the study show the limitations of classifying patients as high risk or low risk for 1:1 AFL. Atrial fibrillation often converts to AFL under pharmacological therapy; therefore, AAs must be administered cautiously along with AV nodal conduction-suppressing agents at adequate doses in patients with AF. Conclusions Clinicians should be aware of the risk of 1:1 AV conduction in AFL patients, particularly in those with remarkable prolongation of the CL in addition to essentially enhanced AV conduction properties. It is better to avoid administration of AAs in such patients and to treat them with catheter ablation of the cavo-tricuspid isthmus. Conflict of interest: none declared. References 1. Marcus FI. The hazards of using type Ic antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation. Am J Cardiol 1990;66: Friedman PL, Stevenson WG. Proarrhythmia. Am J Cardiol 1998;82: 50N 58N. 3. Kawabata M, Hirao K, Horikawa T, Suzuki K, Motokawa K, Suzuki F et al. Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs. J Electrocardiol 2001;34: Wiesfeld AC, Ansink JM, van Veldhuisen DJ, van Gelder IC. Broad complex tachycardia during treatment of atrial fibrillation with a 1c antiarrhythmic drug: ventricular or supraventricular proarrhythmia? Int J Cardiol 2006; 107: Feld GK, Chen PS, Nicod P, Fleck P, Meyer D. Possible atrial proarrhythmic effects of class Ic antiarrhythmic drugs. Am J Cardiol 1990;66: Aouate P, Elbaz N, Klug D, Lacotte J, Raguin D, Frank R et al. Atrial flutter with 1/1 nodo-ventricular conduction with amiodarone from physiopathology to diagnosis. Arch Mal Coeur Vaiss 2002;95: (in French).
5 288 M. Kawabata et al. 7. Brembilla-Perrot B, Houriez P, Claudon O, Yassine M, Suty-Selton C, Vancon AC et al. Can the supraventricular proarrhythmic effects of class 1C antiarrhythmic drugs be prevented with the association of beta blockers? Ann Cardiol Angeiol (Paris) 2000;49: (in French). 8. Velebit V, Podrid P, Lown B, Cohen BH, Graboys TB. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 1982;65: Torres V, Flowers D, Somberg JC. The arrhythmogenicity of antiarrhythmic agents. Am Heart J 1985;109: Creamer JE, Nathan AW, Camm AJ. The proarrhythmic effects of antiarrhythmic drugs. Am Heart J 1987;114: Kerin NZ, Somberg S. Proarrhythmia: definition, risk factors, causes, treatment and controversies. Am Heart J 1994;126: The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New Engl J Med 1989;321: Kennelly BM, Lane GK. Electrophysiological studies in four patients with atrial flutter with 1:1 atrioventricular conduction. Am Heart J 1978;96: Aranda JM, Moleiro F, Castellanos A, Befeler B. Electrophysiologic studies in a patient with atrial flutter and 1:1 atrioventricular conduction. Chest 1975;68: Castellanos A, Vagueiro MC, Befeler B, Myerburg RJ. Syndrome of short P-R, narrow QRS and repetitive supraventricular tachyarrhythmias: the possible occurrence of the R-on-T phenomenon and the limits of this syndrome. Eur J Cardiol 1975;2: Lister JW, Stein E, Kosowsky BD, Lau SH, Damato AN. Atrioventricular conduction in man. Effect of rate, exercise, isoproterenol and atropine on the P-R interval. Am J Cardiol 1965;16: Brembilla-Perrot B, Houriez P, Beurrier D, Claudon O, Terrier de la Chaise A, Louis P. Predictors of atrial flutter with 1:1 conduction in patients treated with class I antiarrhythmic drugs for atrial tachyarrhythmias. Int J Cardiol 2001;80:7 15.
The pill-in-the-pocket strategy for paroxysmal atrial fibrillation
The pill-in-the-pocket strategy for paroxysmal atrial fibrillation KONSTANTINOS P. LETSAS, MD, FEHRA LABORATORY OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL OF ATHENS ARRHYTHMIAS UPDATE,
More informationAntiarrhythmic Drugs
Antiarrhythmic Drugs DR ATIF ALQUBBANY A S S I S T A N T P R O F E S S O R O F M E D I C I N E / C A R D I O L O G Y C O N S U L T A N T C A R D I O L O G Y & I N T E R V E N T I O N A L E P A C H D /
More informationRhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014
Rhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014 Financial disclosures Consultant Medtronic 3 reasons to evaluate and treat arrhythmias
More informationClinical Efficacy of Bepridil for Class I Antiarrhythmic Drug-Induced Atrial Flutter in Patients with Paroxysmal Atrial Fibrillation
Original Article Clinical Efficacy of Bepridil for Class I Antiarrhythmic Drug-Induced Atrial Flutter in Patients with Paroxysmal Atrial Fibrillation Hidemori Hayashi MD 1, Masataka Sumiyoshi MD 1, Satoru
More informationPediatrics ECG Monitoring. Pediatric Intensive Care Unit Emergency Division
Pediatrics ECG Monitoring Pediatric Intensive Care Unit Emergency Division 1 Conditions Leading to Pediatric Cardiology Consultation 12.7% of annual consultation Is arrhythmias problems Geggel. Pediatrics.
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationARRHYTHMIAS IN THE ICU
ARRHYTHMIAS IN THE ICU Nora Goldschlager, MD MACP, FACC, FAHA, FHRS SFGH Division of Cardiology UCSF IDENTIFIED VARIABLES IN ARRHYTHMOGENESIS Ischemia/infarction (scar) Electrolyte imbalance Proarrhythmia
More informationArrhythmias (I) Supraventricular Tachycardias. Disclosures
Arrhythmias (I) Supraventricular Tachycardias Amy Leigh Miller, MD, PhD Cardiovascular Electrophysiology, Brigham & Women s Hospital Disclosures None Short R-P Tachycardia REGULAR with 1:1 P/R relationship
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationARRHYTHMIAS IN THE ICU: DIAGNOSIS AND PRINCIPLES OF MANAGEMENT
ARRHYTHMIAS IN THE ICU: DIAGNOSIS AND PRINCIPLES OF MANAGEMENT Nora Goldschlager, M.D. MACP, FACC, FAHA, FHRS SFGH Division of Cardiogy UCSF CLINICAL VARIABLES IN ARRHYTHMOGENESIS Ischemia/infarction (scar)
More informationArrhythmic Complications of MI. Teferi Mitiku, MD Assistant Clinical Professor of Medicine University of California Irvine
Arrhythmic Complications of MI Teferi Mitiku, MD Assistant Clinical Professor of Medicine University of California Irvine Objectives Brief overview -Pathophysiology of Arrhythmia ECG review of typical
More informationAtrial Fibrillation 10/2/2018. Depolarization & ECG. Atrial Fibrillation. Hemodynamic Consequences
Depolarization & ECG Atrial Fibrillation How to make ORDER out of CHAOS Julia Shih, VMD, DACVIM (Cardiology) October 27, 2018 Depolarization & ECG Depolarization & ECG Atrial Fibrillation Hemodynamic Consequences
More informationIntraoperative and Postoperative Arrhythmias: Diagnosis and Treatment
Intraoperative and Postoperative Arrhythmias: Diagnosis and Treatment Karen L. Booth, MD, Lucile Packard Children s Hospital Arrhythmias are common after congenital heart surgery [1]. Postoperative electrolyte
More informationBernard Belhassen, MD; Roman Fish, MD; Sami Viskin, MD; Aharon Glick, MD; Michael Glikson, MD; Michael Eldar, MD
www.ipej.org 3 Original Article Incidence of Dual AV Node Physiology Following Termination of AV Nodal Reentrant Tachycardia by Adenosine-5'-Triphosphate: A Comparison with Drug Administration in Sinus
More informationAF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire
AF and arrhythmia management Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire Atrial fibrillation Paroxysmal AF recurrent AF (>2 episodes) that
More informationΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ. ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C
ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C Definitions of AF: A Simplified Scheme Term Definition Paroxysmal AF AF that terminates
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationAtrioventricular (AV) Nodal Reentry Associated with 2:1 Infra-His Conduction Block during Tachycardia in a Patient with AV Nodal Triple Pathways
Atrioventricular (AV) Nodal Reentry Associated with 2:1 Infra-His Conduction Block during Tachycardia in a Patient with AV Nodal Triple Pathways Haruhiko ABE, M.D., Takashi OHKITA, M.D., Masasuke FUJITA,
More informationTACHYARRHYTHMIAs. Pawel Balsam, MD, PhD
TACHYARRHYTHMIAs Pawel Balsam, MD, PhD SupraVentricular Tachycardia Atrial Extra Systole Sinus Tachycardia Focal A. Tachycardia AVRT AVNRT Atrial Flutter Atrial Fibrillation Ventricular Tachycardia Ventricular
More informationMedical management of AF: drugs for rate and rhythm control
Medical management of AF: drugs for rate and rhythm control Adel Khalifa Sultan Hamad, BMS, MD, FGHRS, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist Head of Electrophysiology
More informationSupraventricular Tachycardia (SVT)
Supraventricular Tachycardia (SVT) Bruce Stambler, MD Piedmont Heart Atlanta, GA Supraventricular Tachycardia Objectives Types and mechanisms AV nodal reentrant tachycardia (AVNRT) AV reciprocating tachycardia
More informationAF Today: W. For the majority of patients with atrial. are the Options? Chris Case
AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial
More informationPatient Examination. Objectives for Presentation RECOGNITION OF COMMON ARRHYTHMIAS THEIR CAUSES AND TREATMENT OPTIONS 9/8/2016
RECOGNITION OF COMMON ARRHYTHMIAS THEIR CAUSES AND TREATMENT OPTIONS Ryan Fries, DVM, DACVIM (Cardiology) Clinical Assistant Professor University of Illinois Department of Clinical Veterinary Medicine
More informationChapter 16: Arrhythmias and Conduction Disturbances
Complete the following. Chapter 16: Arrhythmias and Conduction Disturbances 1. Cardiac arrhythmias result from abnormal impulse, abnormal impulse, or both mechanisms together. 2. is the ability of certain
More informationLecture outline. Electrical properties of the heart. Automaticity. Excitability. Refractoriness. The ABCs of ECGs Back to Basics Part I
Lecture outline The ABCs of ECGs Back to Basics Part I Meg Sleeper VMD, DACVIM (cardiology) University of Florida Veterinary School Electrical properties of the heart Action potentials Normal intracardiac
More informationI have nothing to disclose.
I have nothing to disclose. Antiarrhythmic Therapy in Pregnancy Prof. Ali Oto,MD,FESC,FACC,FHRS Department of Cardiology Hacettepe University,Faculty of Medicine Ankara Arrhythmias in pregnancy An increased
More informationChapter 9. Learning Objectives. Learning Objectives 9/11/2012. Cardiac Arrhythmias. Define electrical therapy
Chapter 9 Cardiac Arrhythmias Learning Objectives Define electrical therapy Explain why electrical therapy is preferred initial therapy over drug administration for cardiac arrest and some arrhythmias
More informationUse of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital
Use of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital Content i. Rhythm versus Rate control ii. Anti-arrhythmic for Rhythm Control iii. Anti-arrhythmic for Rate
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review
More informationAtrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology
Atrial Fibrillation: Rate vs. Rhythm Michael Curley, MD Cardiac Electrophysiology I have no relevant financial disclosures pertaining to this topic. A Fib Epidemiology #1 Most common heart rhythm disturbance
More informationCardiac arrhythmias. Janusz Witowski. Department of Pathophysiology Poznan University of Medical Sciences. J. Witowski
Cardiac arrhythmias Janusz Witowski Department of Pathophysiology Poznan University of Medical Sciences A 68-year old man presents to the emergency department late one evening complaining of increasing
More informationWide QRS Tachycardia in a Dual Chamber Pacemaker Patient: What is the Mechanism?
CASE REPORTS Arrhythmia 2015;16(3):173-177 doi: http://dx.doi.org/10.18501/arrhythmia.2015.029 Wide QRS Tachycardia in a Dual Chamber Pacemaker Patient: What is the Mechanism? Eun-Sun Jin, MD, PhD Cardiovascular
More informationCardiac Arrhythmias. For Pharmacists
Cardiac Arrhythmias For Pharmacists Agenda Overview of the normal Classification Management Therapy Conclusion Cardiac arrhythmias Overview of the normal Arrhythmia: definition From the Greek a-, loss
More informationNathan Cade, MD Brandon Fainstad, MD Andrew Prouse, MD
Nathan Cade, MD Brandon Fainstad, MD Andrew Prouse, MD OBJECTIVES 1. Identify the basic electrophysiology of the four causes of wide complex tachycardia. 2. Develop a simple framework for acute management
More informationArrhythmias. Simple-dysfunction cause abnormalities in impulse formation and conduction in the myocardium.
Arrhythmias Simple-dysfunction cause abnormalities in impulse formation and conduction in the myocardium. However, in clinic it present as a complex family of disorders that show variety of symptoms, for
More informationDrugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification
Drugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification Class I Na Channel Blockers Flecainide Propafenone Class III K channel Blockers Dofetilide,
More informationAtrial Fibrillation and Common Supraventricular Tachycardias. Sunil Kapur MD
Atrial Fibrillation and Common Supraventricular Tachycardias Sunil Kapur MD Cardiac Electrophysiology Brigham and Women s Hospital Instructor, Harvard Medical School No disclosures Cardiac Conduction:
More informationSustained tachycardia with wide QRS
Sustained tachycardia with wide QRS Courtesy from Prof. Antonio Américo Friedmann. Electrocardiology Service of University of Faculty of São Paulo. Opinions from colleagues Greetings to everyone, In a
More informationClinical Cardiac Electrophysiology
Clinical Cardiac Electrophysiology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of
More informationANTI-ARRHYTHMICS AND WARFARIN. Dr Nithish Jayakumar
ANTI-ARRHYTHMICS AND WARFARIN Dr Nithish Jayakumar Contents 1. Anti-arrhythmics Pacemaker and myocardial potentials Drug classes mechanisms; s/e; contra-indications Management of common arrhythmias 2.
More information«Aσθενής με ασυμπτωματικό WPW και παροξυσμική κολπική μαρμαρυγή» Χάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ.
«Aσθενής με ασυμπτωματικό WPW και παροξυσμική κολπική μαρμαρυγή» Χάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ. ΓΕΝΝΗΜΑΤΑΣ» the primary mechanism of SCD in patients with WPW is the rapid conduction
More information1 Cardiology Acute Care Day 22 April 2013 Arrhythmia Tutorial Course Material
1 Cardiology Acute Care Day 22 April 2013 Arrhythmia Tutorial Course Material Arrhythmia recognition This tutorial builds on the ECG lecture and provides a framework for approaching any ECG to allow the
More informationEP WIRE on Management Preexcitation syndromes
EP WIRE on Management Preexcitation syndromes 1. Is your Institution: A University Hospital 70.7% 41 A Private Hospital 13.8% 8 Other Type of Hospital 15.5% 9 Institution name: 50 answered question 58
More informationDECLARATION OF CONFLICT OF INTEREST. Consultant Sanofi Biosense Webster Honorarium Boehringer Ingelheim St Jude Medical
DECLARATION OF CONFLICT OF INTEREST Consultant Sanofi Biosense Webster Honorarium Boehringer Ingelheim St Jude Medical ESC Congress Paris, France August 27-31, 2011 Risk & Complications of AADs for Rhythm
More informationCore Content In Urgent Care Medicine
Palpitations/Arrhythmias Ebrahim Barkoudah, MD Clinical Instructor in Internal Medicine Harvard Medical School Assistant in Internal Medicine & Pediatrics Massachusetts General Hospital MGH Chelsea Chelsea,
More informationPHARMACOLOGY OF ARRHYTHMIAS
PHARMACOLOGY OF ARRHYTHMIAS Course: Integrated Therapeutics 1 Lecturer: Dr. E. Konorev Date: November 27, 2012 Materials on: Exam #5 Required reading: Katzung, Chapter 14 1 CARDIAC ARRHYTHMIAS Abnormalities
More informationChapter 26. Media Directory. Dysrhythmias. Diagnosis/Treatment of Dysrhythmias. Frequency in Population Difficult to Predict
Chapter 26 Drugs for Dysrythmias Slide 33 Slide 35 Media Directory Propranolol Animation Amiodarone Animation Upper Saddle River, New Jersey 07458 All rights reserved. Dysrhythmias Abnormalities of electrical
More informationMEDICINAL PRODUCTS FOR THE TREATMENT OF ARRHYTHMIAS
MEDICINAL PRODUCTS FOR THE TREATMENT OF ARRHYTHMIAS Guideline Title Medicinal Products for the Treatment of Arrhythmias Legislative basis Directive 75/318/EEC as amended Date of first adoption November
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More informationSelf-assessment corner
Postgrad Med J 1995; 71: 181-185 C) The Fellowship of Postgraduate Medicine, 1995 Self-assessment corner Department of Cardiology, Royal Liverpool University Hospital, Liverpool L7 8XP, UK SS Mushahwar
More informationMr. Eknath Kole M.S. Pharm (NIPER Mohali)
M.S. Pharm (NIPER Mohali) Drug Class Actions Therapeutic Uses Pharmacokinetics Adverse Effects Other Quinidine IA -Binds to open and inactivated Na+ -Decreases the slope of Phase 4 spontaneous depolarization
More informationCase Report Catheter Ablation of Long-Lasting Accelerated Idioventricular Rhythm in a Patient with Mild Left Ventricular Dysfunction
Volume 2012, Article D 143864, 4 pages doi:10.1155/2012/143864 Case Report Catheter Ablation of Long-Lasting Accelerated dioventricular Rhythm in a Patient with Mild Left Ventricular Dysfunction Takanao
More informationRecurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm
Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm Guy Amit, MD, MPH Soroka University Medical Center Ben-Gurion University of the Negev Beer-Sheva, Israel Disclosures Consultant:
More informationEHRA Accreditation Exam - Sample MCQs Invasive cardiac electrophysiology
EHRA Accreditation Exam - Sample MCQs Invasive cardiac electrophysiology Dear EHRA Member, Dear Colleague, As you know, the EHRA Accreditation Process is becoming increasingly recognised as an important
More informationPEDIATRIC SVT MANAGEMENT
PEDIATRIC SVT MANAGEMENT 1 INTRODUCTION Supraventricular tachycardia (SVT) can be defined as an abnormally rapid heart rhythm originating above the ventricles, often (but not always) with a narrow QRS
More informationthe ECG, 6 mg of intravenous adenosine was administered as a fast bolus through a large bore intravenous cannula in
(arrows). Electrocardiography Series Singapore Med.1 2011, 52(3) 146 CME Article Regular narrow complex tachycardia Singh D, Teo S G, Poh K K V Hr JL1 11 VL VF WA, Fig. I ECG shows regular narrow complex
More informationControversies in Atrial Fibrillation and HF
Controversies in Atrial Fibrillation and HF Dr.Yahya Al Hebaishi Cardiac electrophysiology division, PSCC, Riyadh Atrial Fibrillation: Rate or Rhythm? HF and AF: the twin epidemic of cardiovascular disease.
More informationDysrhythmias 11/7/2017. Disclosures. 3 reasons to evaluate and treat dysrhythmias. None. Eliminate symptoms and improve hemodynamics
Dysrhythmias CYDNEY STEWART MD, FACC NOVEMBER 3, 2017 Disclosures None 3 reasons to evaluate and treat dysrhythmias Eliminate symptoms and improve hemodynamics Prevent imminent death/hemodynamic compromise
More informationChapter 14. Agents used in Cardiac Arrhythmias
Chapter 14 Agents used in Cardiac Arrhythmias Cardiac arrhythmia Approximately 50% of post-myocardial infarction fatalities result from ventricular tachycarida (VT) or ventricular fibrillation (VF). These
More informationThere are future perspectives in the pharmacological treatment of arrhythmias
There are future perspectives in the pharmacological treatment of arrhythmias George Andrikopoulos, MD, PhD, FESC, Cardiologist, Director, 1st Department of Cardiology/ Department of Electrophysiology
More informationEHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs
EHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs Dear EHRA Member, Dear Colleague, As you know, the EHRA Accreditation Process is becoming increasingly recognised as an important step for
More informationParoxysmal Supraventricular Tachycardia PSVT.
Atrial Tachycardia; is the name for an arrhythmia caused by a disorder of the impulse generation in the atrium or the AV node. An area in the atrium sends out rapid signals, which are faster than those
More informationVentricular arrhythmias
Ventricular arrhythmias Assoc.Prof. Lucie Riedlbauchová, MD, PhD Department of Cardiology University HospitalMotol and2nd FacultyofMedicine, Charles University in Prague Definition and classification Ventricular
More informationPractical Approach to Arrhythmias
Outline Practical Approach to Arrhythmias Julia Shih, VMD, DACVIM (Cardiology) October 27, 2018 Conduction System ECG Acquisition ECG Interpretation Heart rate Rhythm Arrhythmias Tachyarrhythmias Supraventricular
More informationLa terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO
La terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO Rhythm or rate control strategy? N Engl J Med 2002;347:1834 40 Rate Control versus Electrical Cardioversion for Persistent
More informationS. Riva, C. Tondo, C. Carbucicchio, P. Galimberti, G. Fassini and P. Della Bella
Europace (1999) 1, 242 247 Incidence and clinical significance of transformation of atrial fibrillation to atrial flutter in patients undergoing long-term antiarrhythmic drug treatment S. Riva, C. Tondo,
More informationIncessant Tachycardia Using a Concealed Atrionodal Bypass Tract
191 Incessant Tachycardia Using a Concealed Atrionodal Bypass Tract ADAM ZIVIN, M.D., atid FRED MORADY, M.D. From the Division of Cardiology. Department of Internal Medicine, University of Michigan Medical
More informationAnti arrhythmic drugs. Hilal Al Saffar College of medicine Baghdad University
Anti arrhythmic drugs Hilal Al Saffar College of medicine Baghdad University Mechanism of Arrhythmia Abnormal heart pulse formation Abnormal heart pulse conduction Classification of Arrhythmia Abnormal
More informationCLINICAL CARDIAC ELECTROPHYSIOLOGY Maintenance of Certification (MOC) Examination Blueprint
CLINICAL CARDIAC ELECTROPHYSIOLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Clinical Cardiac Electrophysiology MOC exam blueprint Based on feedback
More informationBasics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY
Basics of Atrial Fibrillation By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY Atrial Fibrillation(AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation
More informationand fibrillation in pre-excitation (Wolff-Parkinson-
British Heart Journal, 973, 35, 8ii-8i6. Factors regulating ventricular rates during atrial flutter and fibrillation in pre-excitation (Wolff-Parkinson- White) syndrome Agustin Castellanos, Jr., Robert
More informationCase Report Mahaim Fiber Accelerated Automaticity and Clues to a Mahaim Fiber Being Morphologically an Ectopic or a Split AV Node
www.ipej.org 62 Case Report Mahaim Fiber Accelerated Automaticity and Clues to a Mahaim Fiber Being Morphologically an Ectopic or a Split AV Node Shomu Bohora, Narayanan Namboodiri, Santosh Dora, VK Ajit
More informationArrhythmias. 1. beat too slowly (sinus bradycardia). Like in heart block
Arrhythmias It is a simple-dysfunction caused by abnormalities in impulse formation and conduction in the myocardium. The heart is designed in such a way that allows it to generate from the SA node electrical
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01133-5 Coronary
More informationWhat s new in my specialty?
What s new in my specialty? Jon Melman, MD Heart Rhythm Specialists McKay-Dee Hospital some would say some would say my specialty 1 some would say my specialty First pacemaker 1958 some would say my specialty
More information小児および若年者の特発性心房粗動, 心房細動の頻度と特徴 臨床群と誘発群の比較検討
原 著 PEDIATRIC CARDIOLOGY and CARDIAC SURGERY VOL. 26 NO. 4 (332 337) 小児および若年者の特発性心房粗動, 心房細動の頻度と特徴 臨床群と誘発群の比較検討 key words: atrial flutter, atrial fibrillation, electrophysiological study, radiofrequency
More informationDysrhythmias. Dysrythmias & Anti-Dysrhythmics. EKG Parameters. Dysrhythmias. Components of an ECG Wave. Dysrhythmias
Dysrhythmias Dysrythmias & Anti-Dysrhythmics Rhythm bad in the heart: Whitewater rafting Electrical impulses coordinate heart Reduction in Cardiac Output PEA Asystole Components of an ECG Wave EKG Parameters
More informationVentricular ectopic activity after premature atrial beats
British Heart Journal, 1977, 39, 1033-1037 Ventricular ectopic activity after premature atrial beats in acute myocardial infarction1 R. J. MYERBURG, R. J. SUNG, G. GERSTENBLITH, STEPHEN M. MALLON, AND
More informationPARA-HISSIAN CONCEALED ACCESSORY PATHWAY
PARA-HISSIAN CONCEALED ACCESSORY PATHWAY Anamnestic Findings 41 y.o. man with normal cardiac findings on echocardiography, suffering for paroxysmal supra-ventricular tachycardia since 1982 with rapid onset
More informationDiploma in Electrocardiography
The Society for Cardiological Science and Technology Diploma in Electrocardiography The Society makes this award to candidates who can demonstrate the ability to accurately record a resting 12-lead electrocardiogram
More informationStep by step approach to EKG rhythm interpretation:
Sinus Rhythms Normal sinus arrhythmia Small, slow variation of the R-R interval i.e. variation of the normal sinus heart rate with respiration, etc. Sinus Tachycardia Defined as sinus rhythm with a rate
More informationUNDERSTANDING YOUR ECG: A REVIEW
UNDERSTANDING YOUR ECG: A REVIEW Health professionals use the electrocardiograph (ECG) rhythm strip to systematically analyse the cardiac rhythm. Before the systematic process of ECG analysis is described
More informationEmergency Medical Training Services Emergency Medical Technician Paramedic Program Outlines Outline Topic: WPW Revised: 11/2013
Emergency Medical Training Services Emergency Medical Technician Paramedic Program Outlines Outline Topic: WPW Revised: 11/2013 Wolff-Parkinson-White syndrome (WPW) is a syndrome of pre-excitation of the
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationARRHYTHMIAS IN THE INTENSIVE CARE UNIT
ARRHYTHMIAS IN THE INTENSIVE CARE UNIT Nicole Van Israël, DVM, CESOpht, CertSAM, CertVC, DECVIM-CA (Cardiology), MSc, MRCVS European Specialist in Veterinary Cardiology Animal CardioPulmonary Consultancy
More informationAntiarrhythmic Drugs 1/31/2018 1
Antiarrhythmic Drugs 1/31/2018 1 Normal conduction pathway: 1- SA node generates action potential and delivers it to the atria and the AV node 2- The AV node delivers the impulse to purkinje fibers Other
More informationMANAGEMENT OF ASYMPTOMATIC BRADYCARDIA. Pr. HABIB HAOUALA Service de Cardiologie Hôpital militaire de Tunis
MANAGEMENT OF ASYMPTOMATIC BRADYCARDIA Pr. HABIB HAOUALA Service de Cardiologie Hôpital militaire de Tunis DISCLOSURE STATEMENT OF FINANCIAL INTEREST Grant/research: Medtronic;Sanofi; Novartis Consulting
More informationABLATION OF CHRONIC AF
ABLATION OF CHRONIC AF A PISAPIA ST JOSEPH HOSPITAL MARSEILLE MEET 2008 Atrial Fibrillation The most common significant heart rhythm disturbance Incidence increases with age and the development of structural
More informationwith flecainide acetate
Archives of Disease in Childhood, 1987, 62, 247-252 Treatment of refractory supraventricular arrhythmias with flecainide acetate J A TILL, E ROWLAND, E A SHINEBOURNE, AND D E WARD Department of Paediatric
More informationECG S: A CASE-BASED APPROACH December 6,
ECG S: A CASE-BASED APPROACH December 6, 2018 1 Faculty Disclosure Faculty: Lorne Gula MD, FRCPC Professor, Western University Cardiologist, Hearth Rhythm Specialist Director, Electrophysiology Laboratory,
More informationAtrial Fibrillation Cases. Dr Paul Broadhurst Consultant Cardiologist
Atrial Fibrillation Cases Dr Paul Broadhurst Consultant Cardiologist November 2011 Mr TH age 72 Routine medical for hypertension check Denies any symptoms despite close questioning PMH: hypertension, MI,
More informationVentricular tachycardia Ventricular fibrillation and ICD
EKG Conference Ventricular tachycardia Ventricular fibrillation and ICD Samsung Medical Center CCU D.I. Hur Ji Won 2006.05.20 Ventricular tachyarrhythmia ventricular tachycardia ventricular fibrillation
More informationHeart Rhythm Congress October GUCH Arrhythmias. why, what and which drugs are best. Dr Graham Stuart Bristol Congenital Heart Unit
Heart Rhythm Congress October 2016 why, what and which drugs are best Dr Graham Stuart Bristol Congenital Heart Unit why, what,which drugs are best Digitalis 1785 Withering W An account of the Foxglove
More informationEKG Competency for Agency
EKG Competency for Agency Name: Date: Agency: 1. The upper chambers of the heart are known as the: a. Atria b. Ventricles c. Mitral Valve d. Aortic Valve 2. The lower chambers of the heart are known as
More informationCase Report Coexistence of Atrioventricular Nodal Reentrant Tachycardia and Idiopathic Left Ventricular Outflow-Tract Tachycardia
www.ipej.org 149 Case Report Coexistence of Atrioventricular Nodal Reentrant Tachycardia and Idiopathic Left Ventricular Outflow-Tract Tachycardia Majid Haghjoo, M.D, Arash Arya, M.D, Mohammadreza Dehghani,
More informationSuccessful treatment of tachycardia-induced cardiomyopathy secondary to dual atrioventricular nodal nonreentrant tachycardia using cryoablation
Successful treatment of tachycardia-induced cardiomyopathy secondary to dual atrioventricular nodal nonreentrant tachycardia using cryoablation Harold Rivner, MD, * Chris Healy, MD, Raul D. Mitrani, MD,
More informationΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ. ΥΠΕΡ. Michalis Efremidis MD Second Department of Cardiology Evangelismos General Hospital
ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ. ΥΠΕΡ. Michalis Efremidis MD Second Department of Cardiology Evangelismos General Hospital Rate control versus Rhythm control for Atrial Fibrillation AFFIRM N Engl J Med 2002;347:1825-33
More informationCurrent Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Current Guideline for AF Treatment Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Case 1 59 year-old lady Sudden palpitation and breathlessness for 12 hours
More informationECG QUIZ Luc DE ROY Brussels Belgium Disclosure in relation to this topic: none
ECG QUIZ Luc DE ROY Brussels Belgium Disclosure in relation to this topic: none TEST EXAMPLE What is the colour of this rectangle? 1. Blue? 2. Red? 3. Purple? 4. Green? 5. Yellow? 6. 1 and 3? 7. Any of
More informationHow do arrhythmias occur?
How do arrhythmias occur? An arrhythmia is an abnormal heart rhythm (= dysrhythmia). Can be fast (tachy) or slow (brady). Brady arrhythmias are usually due to conduc;on block, while tachyarrhythmias are
More information